文献速递腹部技术与安全CT

人工智能预测胰腺导管腺癌CT淋巴结转移

Artificial Intelligence to Predict Lymph Node Metastasis at CT in Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · Radiology · 2022-09-06

本研究回顾性纳入734例手术病理确诊的胰腺导管腺癌患者,基于多排CT开发并验证自动术前AI算法分割肿瘤和淋巴结以预测淋巴结转移。AI模型在验证集AUC为0.92,优于放射科医师(0.65)、临床模型(0.77)和影像组学模型(0.68),且AI预测阳性与更差生存相关(HR 1.46)。

要点

  • AI模型自动分割肿瘤和淋巴结,验证集预测淋巴结转移AUC达0.92。
  • AI模型显著优于放射科医师(AUC 0.65)及临床、影像组学模型(AUC 0.77、0.68)。

核心结论

  • AI模型在CT预测胰腺导管腺癌淋巴结转移方面优于放射科医师、临床模型和影像组学模型,且AI预测阳性与更差生存相关。

研究设计与样本

  • 回顾性研究纳入734例手术切除病理确诊的胰腺导管腺癌患者(平均年龄62±9岁,453例男性),均行多排CT检查。
  • 患者分为训练集545例和验证集189例,开发了AI模型、临床模型和影像组学模型三个模型。
  • CT判断淋巴结转移由放射科医师诊断,临床和影像组学模型采用多变量逻辑回归分析开发。

关键影像表现/征象

  • AI模型自动分割肿瘤和淋巴结,训练集AUC 0.91、验证集AUC 0.92预测淋巴结转移。
  • 放射科医师诊断淋巴结转移训练集AUC 0.58、验证集AUC 0.65。
  • 临床模型训练集AUC 0.76、验证集AUC 0.77;影像组学模型训练集AUC 0.71、验证集AUC 0.68。

诊断标准与关键数值

  • AI模型预测淋巴结转移验证集AUC 0.92,训练集AUC 0.91。
  • 放射科医师诊断淋巴结转移验证集AUC 0.65,训练集AUC 0.58。
  • 临床模型验证集AUC 0.77,训练集AUC 0.76;影像组学模型验证集AUC 0.68,训练集AUC 0.71。
  • AI模型、放射科医师、临床模型和影像组学模型间验证集AUC差异P < .001。

临床应用与阅片要点

  • AI模型可自动分割肿瘤和淋巴结,减少手动选择层面和分割的方法学障碍,辅助术前预测淋巴结转移。
  • AI预测淋巴结转移阳性提示预后更差,可辅助临床决策和预后分层。

局限性

  • 回顾性研究设计,样本来自单中心(原文未明确多中心)。
  • 依赖手术切除病理确诊患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Although deep learning has brought revolutionary changes in health care, reliance on manually selected cross-sectional images and segmentation remain methodological barriers. Purpose To develop and validate an automated preoperative artificial intelligence (AI) algorithm for tumor and lymph node (LN) segmentation with CT imaging for prediction of LN metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and Methods In this retrospective study, patients with surgically resected, pathologically confirmed PDAC underwent multidetector CT from January 2015 to April 2020. Three models were developed, including an AI model, a clinical model, and a radiomics model. CT-determined LN metastasis was diagnosed by radiologists. Multivariable logistic regression analysis was conducted to develop the clinical and radiomics models. The performance of the models was determined on the basis of their discrimination and clinical utility. Kaplan-Meier curves, the log-rank test, or Cox regression were used for survival analysis. Results Overall, 734 patients (mean age, 62 years ± 9 [SD]; 453 men) were evaluated. All patients were split into training (n = 545) and validation (n = 189) sets. Patients who had LN metastasis (LN-positive group) accounted for 340 of 734 (46%) patients. In the training set, the AI model showed the highest performance (area under the receiver operating characteristic curve [AUC], 0.91) in the prediction of LN metastasis, whereas the radiologists and the clinical and radiomics models had AUCs of 0.58, 0.76, and 0.71, respectively. In the validation set, the AI model showed the highest performance (AUC, 0.92) in the prediction of LN metastasis, whereas the radiologists and the clinical and radiomics models had AUCs of 0.65, 0.77, and 0.68, respectively (P < .001). AI model-predicted positive LN metastasis was associated with worse survival (hazard ratio, 1.46; 95% CI: 1.13, 1.89; P = .004). Conclusion An artificial intelligence model outperformed radiologists and clinical and radiomics models for prediction of lymph node metastasis at CT in patients with pancreatic ductal adenocarcinoma. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Chu and Fishman in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Bian, Zheng, Fang, et al. Artificial Intelligence to Predict Lymph Node Metastasis at CT in Pancreatic Ductal Adenocarcinoma. Radiology. 2022. PMID: 36066369. doi:10.1148/radiol.220329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。